Literature DB >> 25849832

Incomplete immune reconstitution despite virologic suppression in HIV-1 infected children and adolescents.

Paul Krogstad1, Kunjal Patel, Brad Karalius, Rohan Hazra, Mark J Abzug, James Oleske, George R Seage, Paige L Williams, William Borkowsky, Andrew Wiznia, Jorge Pinto, Russell B Van Dyke.   

Abstract

OBJECTIVES: Some perinatally infected children do not regain normal CD4(+) T-cell counts despite suppression of HIV-1 plasma viremia by antiretroviral therapy (ART). The frequency, severity and significance of these discordant treatment responses remain unclear.
DESIGN: We examined the persistence of CD4(+) lymphocytopenia despite virologic suppression in 933 children (≥ 5 years of age) in the USA, Latin America and the Caribbean.
METHODS: CD4(+) T-cell trajectories were examined and Kaplan-Meier methods used to estimate median time to CD4(+) T-cell count at least 500 cells/μl.
RESULTS: After 1 year of virologic suppression, most (99%) children achieved a CD4(+) T-cell count of at least 200 cells/μl, but CD4(+) T-cell counts remained below 500 cells/μl after 1 and 2 years of virologic suppression in 14 and 8% of children, respectively. Median times to first CD4(+) T-cell count at least 500 cells/μl were 1.29, 0.78 and 0.46 years for children with less than 200, 200-349 and 350-499 cells/μl at the start of virologic suppression. New AIDS-defining events occurred in nine children, including four in the first 6 months of virologic suppression. Other infectious and HIV-related diagnoses occurred more frequently and across a wide range of CD4(+) cell counts.
CONCLUSION: ART improved CD4(+) cell counts in most children, but the time to CD4(+) cell count of at least 500 cells was highly dependent upon baseline immunological status. Some children did not reach a CD4(+) T-cell count of 500 cells/μl despite 2 years of virologic suppression. AIDS-defining events occurred in 1% of the population, including children in whom virologic suppression and improved CD4(+) T-cell counts were achieved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25849832      PMCID: PMC4391276          DOI: 10.1097/QAD.0000000000000598

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  33 in total

1.  Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.

Authors:  Richard M Rutstein; Kelly A Gebo; Patricia M Flynn; John A Fleishman; Victoria L Sharp; George K Siberry; Stephen A Spector
Journal:  Med Care       Date:  2005-09       Impact factor: 2.983

2.  Immune reconstitution after receipt of highly active antiretroviral therapy in children with advanced or progressive HIV disease and complete or partial viral load response.

Authors:  Andrea Kovacs; Grace Montepiedra; Vincent Carey; Savita Pahwa; Adriana Weinberg; Lisa Frenkel; Edmund Capparelli; Lynne Mofenson; Elizabeth Smith; Kenneth McIntosh; Sandra K Burchett
Journal:  J Infect Dis       Date:  2005-06-14       Impact factor: 5.226

3.  Early triple therapy vs mono or dual therapy for children with perinatal HIV infection.

Authors:  Elena Chiappini; Luisa Galli; Clara Gabiano; Pier-Angelo Tovo; Maurizio de Martino
Journal:  JAMA       Date:  2006-02-08       Impact factor: 56.272

4.  Variability of serial absolute and percent CD4+ lymphocyte counts in healthy children born to human immunodeficiency virus 1-infected parents. Military Pediatric HIV Consortium.

Authors:  W V Raszka; G A Meyer; N J Waecker; D P Ascher; R A Moriarty; G W Fischer; M L Robb
Journal:  Pediatr Infect Dis J       Date:  1994-01       Impact factor: 2.129

5.  Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.

Authors:  David M Moore; Robert S Hogg; Benita Yip; Evan Wood; Mark Tyndall; Paula Braitstein; Julio S G Montaner
Journal:  J Acquir Immune Defic Syndr       Date:  2005-11-01       Impact factor: 3.731

6.  Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection.

Authors:  Elena Chiappini; Luisa Galli; Pier-Angelo Tovo; Clara Gabiano; Guido Castelli Gattinara; Alfredo Guarino; Raffaele Badolato; Raffaele Baddato; Carlo Giaquinto; Catiuscia Lisi; Maurizio de Martino
Journal:  AIDS       Date:  2006-01-09       Impact factor: 4.177

7.  Thymic volume, T-cell populations, and parameters of thymopoiesis in adolescent and adult survivors of HIV infection acquired in infancy.

Authors:  Jason C Lee; Maria Ines Boechat; Marvin Belzer; Joseph A Church; Jaime De Ville; Karin Nielsen; Stephanie Weston; Yongzhi Geng; Theresa Dunaway; Christina Kitchen; Paul A Krogstad
Journal:  AIDS       Date:  2006-03-21       Impact factor: 4.177

8.  1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1992-12-18

9.  Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.

Authors:  Patricia M Flynn; Bret J Rudy; Steven D Douglas; Janet Lathey; Stephen A Spector; Jaime Martinez; Margarita Silio; Marvin Belzer; Lawrence Friedman; Lawrence D'Angelo; James McNamara; Janice Hodge; Michael D Hughes; Jane C Lindsey
Journal:  J Infect Dis       Date:  2004-06-18       Impact factor: 5.226

10.  Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy.

Authors:  Salvador Resino; Elena Seoane; Alicia Pérez; Ezequiel Ruiz-Mateos; Manuel Leal; Maria A Muñoz-Fernández
Journal:  BMC Infect Dis       Date:  2006-07-13       Impact factor: 3.090

View more
  10 in total

1.  Association of Risk of Viremia, Immunosuppression, Serious Clinical Events, and Mortality With Increasing Age in Perinatally Human Immunodeficiency Virus-Infected Youth.

Authors:  Anne M Neilan; Brad Karalius; Kunjal Patel; Russell B Van Dyke; Mark J Abzug; Allison L Agwu; Paige L Williams; Murli Purswani; Deborah Kacanek; James M Oleske; Sandra K Burchett; Andrew Wiznia; Miriam Chernoff; George R Seage; Andrea L Ciaranello
Journal:  JAMA Pediatr       Date:  2017-05-01       Impact factor: 16.193

2.  Use and Outcomes of Antiretroviral Monotherapy and Treatment Interruption in Adolescents With Perinatal HIV Infection in Asia.

Authors:  Adam W Bartlett; Pagakrong Lumbiganon; Nia Kurniati; Tavitiya Sudjaritruk; Thahira J Mohamed; Rawiwan Hansudewechakul; Penh S Ly; Khanh H Truong; Thanyawee Puthanakit; Lam V Nguyen; Kulkanya Chokephaibulkit; Viet C Do; Nagalingeswaran Kumarasamy; Nik Khairulddin Nik Yusoff; Moy S Fong; Dewi K Watu; Revathy Nallusamy; Annette H Sohn; Matthew G Law
Journal:  J Adolesc Health       Date:  2019-08-05       Impact factor: 5.012

3.  Supranormal thymic output up to 2 decades after HIV-1 infection.

Authors:  Christian R Aguilera-Sandoval; Otto O Yang; Nebojsa Jojic; Pietro Lovato; Diana Y Chen; Maria Ines Boechat; Paige Cooper; Jun Zuo; Christina Ramirez; Marvin Belzer; Joseph A Church; Paul Krogstad
Journal:  AIDS       Date:  2016-03-13       Impact factor: 4.177

4.  Getting to 90-90-90 in paediatric HIV: What is needed?

Authors:  Mary-Ann Davies; Jorge Pinto; Marlène Bras
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

5.  Recovery of effective HIV-specific CD4+ T-cell activity following antiretroviral therapy in paediatric infection requires sustained suppression of viraemia.

Authors:  Emily Adland; Luisa Mori; Leana Laker; Anna Csala; Maximilian Muenchhoff; Alice Swordy; Masa Mori; Philippa Matthews; Gareth Tudor-Williams; Pieter Jooste; Philip Goulder
Journal:  AIDS       Date:  2018-07-17       Impact factor: 4.177

6.  Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation.

Authors:  Klea Panayidou; Mary-Ann Davies; Nanina Anderegg; Matthias Egger
Journal:  J Int AIDS Soc       Date:  2018-11       Impact factor: 5.396

7.  Early antiretroviral treatment of infants to attain HIV remission.

Authors:  Louise Kuhn; Renate Strehlau; Stephanie Shiau; Faeezah Patel; Yanhan Shen; Karl-Günter Technau; Megan Burke; Gayle Sherman; Ashraf Coovadia; Grace M Aldrovandi; Rohan Hazra; Wei-Yann Tsai; Caroline T Tiemessen; Elaine J Abrams
Journal:  EClinicalMedicine       Date:  2020-01-07

8.  The Impact of microRNA Regulation on Immune Recovery in HIV-1-Infected Patients Treated during Acute Infection: A Pilot Study.

Authors:  Yuping Fu; Yan Liu; Zhiying Liu; Lifeng Liu; Lin Yuan; Xizhao An; Jufeng Sun; Tong Zhang; Hao Wu; Shi Lian; Bin Su
Journal:  Biomed Res Int       Date:  2020-12-03       Impact factor: 3.411

9.  Targeting 90-90-90--don't leave children and adolescents behind.

Authors:  Mary-Ann Davies; Jorge Pinto
Journal:  J Int AIDS Soc       Date:  2015-12-02       Impact factor: 5.396

10.  Immuno-virological response and associated factors amongst HIV-1 vertically infected adolescents in Yaoundé-Cameroon.

Authors:  Joseph Fokam; Serge Clotaire Billong; Franck Jogue; Suzie Moyo Tetang Ndiang; Annie Carole Nga Motaze; Koki Ndombo Paul; Anne Esther Njom Nlend
Journal:  PLoS One       Date:  2017-11-07       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.